Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 58.0 kDa. The protein migrates as 70-105 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Canine PDGF R beta Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human PDGF-BB, premium grade (Cat. No. PDB-H4112) at 1 μg/mL (100 μL/well) can bind Canine PDGF R beta / CD140b, His Tag (Cat. No. PDB-C52H3) with a linear range of 2-78 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Sarcoma, Alveolar Soft Part; Bile Duct Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Hepatic Insufficiency; Bone Neoplasms; Urologic Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Medullary thyroid cancer (MTC); Gallbladder Neoplasms; Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Osteoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Leiomyosarcoma; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Nasopharyngeal Carcinoma | Details |
Becaplermin | RWJ-60235; rhPDGF-BB (Janssen) | Approved | Johnson & Johnson Innovative Medicine | Regranex | United States | Ulcer; Lower extremity diabetic neuropathic ulcers | Smith & Nephew Healthcare Ltd | 1997-12-16 | Diabetic Foot; Diabetic Neuropathies; Lower extremity diabetic neuropathic ulcers; Skin Ulcer; Foot Ulcer; Parkinson Disease; Ulcer; Varicose Ulcer | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors | Details |
Ripretinib | DCC-2618 | Approved | Deciphera | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Neoplasms; Mastocytosis, Systemic; Gastrointestinal Stromal Tumors | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; GB-102; PNU-290940; SU-011248-L-malate salt; PHA-290940; SU-010398; SU-11248 | Approved | Pfizer Inc | 索坦, Sutent | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Solid tumours; Fibromatosis, Aggressive; Ovarian Neoplasms; Kidney Neoplasms; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Leukemia, Myeloid, Accelerated Phase; Leukemia; Fibrosarcoma; Teratoma; Liver Neoplasms; Ependymoma; Lymphoma, T-Cell, Peripheral; Intestinal Neoplasms; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Hemangioblastoma; Carcinoma, Islet Cell; Carcinoma; Pheochromocytoma; Stomach Neoplasms; Pelvic Neoplasms; Esophageal Neoplasms; Leukemia, Hairy Cell; Polycythemia Vera; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Ovarian Epithelial; Glioblastoma; Neurofibromatoses; Small Cell Lung Carcinoma; Adenoma, Islet Cell; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Myelodysplastic Syndromes; Hodgkin Disease; Leukemia, Myelomonocytic, Chronic; Carcinoma, Papil | Details |
Dasatinib Hydrate | NSC-732517; BMS-354825; XS-004 | Approved | Bristol-Myers Squibb Company | 施达赛, Dasynoc, Spricel, Sprycel, Spraysel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Primary Myelofibrosis; Hemangiopericytoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Laryngeal Neoplasms; Lymphoma; Gliosarcoma; Peritoneal Neoplasms; Astrocytoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Sarcoma; Neurofibrosarcoma; Breast Neoplasms; Brain Neoplasms; Melanoma; Leukemia, T-Cell; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Mycosis Fungoides; Heart Arrest; Mastocytosis; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Uterine Neoplasms; Burkitt Lymphoma; Neoplasms, Gonadal Tissue; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplas | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a | Details |
Becaplermin biosimilar (Virchow Group) | Approved | Virchow Group | Healace, Plermin gel | Diabetic Foot | Details | |||||
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Kidney Neoplasms; Recurrence; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Rhabdomyosarcoma; Lymphoma, B-Cell, Marginal Zone; Fibromatosis, Aggressive; Head and Neck Neoplasms; Solid tumours; Leiomyosarcoma; Leukemia, Myeloid; Carcinoma, Renal Cell; Carcinoma; Vipoma; Esophageal Neoplasms; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Carcinoid Tumor; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Insulinoma; Stomach Neoplasms; Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Wilms Tumor; Lymphomatoid Granulomatosis; Colonic Neoplasms; Hypertension, Portal; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Multiple Endo | Details |
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Mastocytosis, Systemic; Leukemia, Mast-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 | Phase 3 Clinical | Pfizer Inc | Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma | Details |
ZSP-1603 | ZSP-1603 | Phase 2 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
KDR2-2 | Phase 2 Clinical | Guangzhou Huiborui Biomedical Technology Co Ltd | Neovascularization, Pathologic; Glaucoma, Neovascular; Corneal Neovascularization | Details | |
KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details | |
Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma | Details |
Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
Metarafenib | Phase 1 Clinical | Guangzhou Nanxin Pharma Co Ltd | Liver Neoplasms; Solid tumours | Details | |
ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Nintedanib Solution for Inhalation | AP02; AP-02 | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis | Details |
Sorafenib/MG-005 | MGD-1509; MG-D-1509 | Tri-Service General Hospital, Metagone Biotech Inc | Details |
This web search service is supported by Google Inc.